Phase 3 study of either ivosidenib monotherapy or azacitidine monotherapy in patients with IDH1-mutant myelodysplastic syndromes who are hypomethylating agent naive (PyramIDH).
Year: 2025
Type: article
Source: Journal of Clinical Oncology
Institutions: Azienda Ospedaliero-Universitaria Careggi, University of Florence, Groupe Francophone des Myélodysplasies, Hôpital Saint-Louis, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Servier
OpenAlex ID: W4410816860